A person's sex is one of the main drivers of altered gene expression in motor neurons, regardless of whether they were derived from patients diagnosed with ALS. Male ALS stem cells generated significantly more motor neurons than the control group, however, this was not seen in female samples.
A newly designed soft robotic wearable is able to provide significant upper arm and shoulder support and improved mobility for those with ALS.
Study links motor neurons' large cell size and supporting structures with genes that underly vulnerability to degeneration associated with ALS.
Lacticaseibacillus rhamnosus HA-114, a non-commercial probiotic reduces neurodegeneration and has neuroprotective effects in lab models of ALS.
With the help of AI, researchers are developing digital biomarkers that use speech data to identify ALS and frontotemporal dementia.
Those working in production occupations, especially those exposed to volatile organic compounds, metals, combustion pollutants, and particulate matter have a higher risk of developing ALS.
Researchers discovered both immune system and central nervous system dysfunction in animal models and people with ALS4, a genetic, juvenile, and slow-progressing form of ALS.
Study reveals an association between intestinal inflammation and the gut microbiome in the development and progression of ALS.
PolyP, an inorganic polyphosphate released by astrocytes in people with ALS and frontotemporal dementia contributes to the signature motor neuron death associated with the disease pathologies.
Mislocalization of the TDP-43 protein alters the genetic instructions for UNC13A. The findings provide a potential new therapeutic target for the treatment of ALS and frontotemporal dementia.
Measuring the level of neurofilaments in the blood may be a reliable biomarker for the early diagnosis of ALS.
In patients with ALS, astrocytes within the brain become pro-inflammatory and tend to lose their protective function, resulting in changes in the ability to uptake glutamate.